<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153488</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000547</org_study_id>
    <nct_id>NCT03153488</nct_id>
  </id_info>
  <brief_title>Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response</brief_title>
  <official_title>Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-month trial in adults to find out if certain neuromarkers can predict individual
      treatment response to stimulant medications for Attention Deficit Hyperactivity Disorder
      (ADHD). Males and females, ages 18-45, will complete an MRI scan at MIT prior to beginning
      medication for ADHD as determined by a treating clinician outside the context of this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD Clinical Global Impressions Scale - Severity (CGI-S)</measure>
    <time_frame>6 months</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADHD Clinical Global Impressions Scale - Improvement (CGI-I)</measure>
    <time_frame>6 months</time_frame>
    <description>The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Connectomic Variation Prediction of Medicine Response</measure>
    <time_frame>6 months</time_frame>
    <description>Examine whether variation in baseline ADHD severity scores and functional connectivity and structural connectivity predict whether an individual ADHD patient will respond better to one of the other stimulant family treatment, both, or neither. An MRI will be completed prior to starting medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amphetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects (ages 18-45) receiving an Amphetamine derivative medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.</description>
    <arm_group_label>Amphetamine</arm_group_label>
    <arm_group_label>Methylphenidate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults ages 18-55

          -  A diagnosis of DSM-V ADHD based on clinical assessment supported by the ADHD module of
             a structured diagnostic interview

          -  Proficiency in English

          -  Right-handed

        Exclusion Criteria:

          -  Any contraindication for the use of a stimulant medication

          -  Investigator and his/her immediate family (spouse, parent, child, grandparent, or
             grandchild)

          -  Any contraindications for MRI examination (metallic implants, such as pacemakers,
             surgical aneurysm clips, or known metal fragments in the body)

          -  Women who are currently pregnant or breastfeeding, as confirmed by a urine pregnancy
             test

          -  Clinically significant abnormal baseline laboratory values, including systolic and
             diastolic blood pressure parameters above 140 and 90, respectively and resting heart
             rate outside 60-100 bpm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Biederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Noyes</last_name>
    <phone>617-724-2551</phone>
    <email>enoyes@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexa Pulli, BS</last_name>
    <phone>617-726-4651</phone>
    <email>apulli@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Noyes</last_name>
      <phone>617-724-2511</phone>
      <email>enoyes@partners.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Biederman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Biederman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Amphetamine</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

